HB 169 establishes a comprehensive regulatory framework for cannabis in Texas, directly affecting licensed cannabis businesses and adults aged 21+ who purchase cannabis products. The bill requires businesses to obtain occupational licenses for cultivation, processing, and sales, mandates product testing and labeling standards, and imposes a tax on cannabis products. It also creates criminal penalties for unlicensed activities and authorizes local fees for cannabis establishments. Key provisions include regulating all aspects of the cannabis supply chain - from grower to consumer - and defining specific terms like "cannabis concentrate" and "cannabis establishment." The bill does not address medical cannabis use but focuses on commercial regulation and taxation.
HB 151 designates carisoprodol (a muscle relaxant), mifepristone, and misoprostol as Schedule IV controlled substances under Texas law. This change would subject these substances to stricter regulation, including prescription requirements and penalties for unauthorized possession or distribution. The bill takes effect January 1, 2026, applying only to offenses committed on or after that date, with prior offenses governed by existing law. It directly affects individuals and providers handling these substances in Texas, requiring compliance with Schedule IV controls.
SB 31, titled the "Texas Regulation of Cannabis Act," proposes comprehensive state-level regulation of cannabis cultivation, sale, and taxation while establishing licensing requirements for businesses. It would require occupational licenses for cannabis growers, testing facilities, and transporters, impose a tax on cannabis products, and provide for expungement of records related to decriminalized cannabis offenses. The bill also mandates a study by state agencies to establish a new commission for cannabis oversight, with findings due by December 2026. This legislation directly affects cannabis businesses, consumers, and law enforcement by creating new regulatory frameworks and record-clearing mechanisms. It does not legalize cannabis use but regulates its commercial activity under state authority.
HB 227 has been filed (2025-08-18) and relates to amending the Texas Controlled Substances Act. The bill's title indicates it would add certain substances to the controlled substances list, regulate kratom and kratom products, and increase both civil and criminal penalties. However, the full bill text is not available in the provided context, so specific substances, exact penalty amounts, or direct affected parties cannot be detailed. Without the complete text, a factual summary of concrete policy changes cannot be provided.
HB 195 would add three substances - carisoprodol (a muscle relaxant), mifepristone (a medication used in medical abortions), and misoprostol (often used with mifepristone for abortions) - to Schedule IV of the Texas Controlled Substances Act. This change would regulate these substances under stricter state drug laws, affecting their legal possession, distribution, and use in Texas. The bill applies only to offenses committed on or after its effective date of January 1, 2026, with prior offenses governed by existing law. The policy change directly impacts healthcare providers, pharmacies, and individuals handling these specific medications within Texas.
